UAB Digital Repository of Documents 6 records found  Search took 0.01 seconds. 
1.
8 p, 594.7 KB The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes : Achieving HbA1c targets with basal insulin in a real-world setting / Meneghini, Luigi F. (Parkland Health & Hospital System) ; Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ; Orsi, Emanuela (Fondazione Ca' Granda IRCCS) ; Lalic, Nebojsa M. (University of Belgrade) ; Cali, Anna M.G. (Sanofi) ; Westerbacka, Jukka (Sanofi) ; Stella, Peter (Sanofi) ; Candelas, Christophe (Sanofi) ; Pilorget, Valerie (Sanofi) ; Perfetti, Riccardo (Sanofi) ; Khunti, Kamlesh (University of Leicester) ; Universitat Autònoma de Barcelona
To describe in a real-world setting the achievement of physician-selected individualized HbA1c targets in individuals with type 2 diabetes, newly or recently initiated with basal insulin, and the association of hypoglycaemia with target achievement. [...]
2019 - 10.1111/dom.13673
Diabetes, Obesity and Metabolism, Vol. 21 Núm. 6 (june 2019) , p. 1429-1436  
2.
12 p, 1.0 MB The importance of the initial period of basal insulin titration in people with diabetes / Khunti, Kamlesh (University of Leicester) ; Giorgino, F. (University of Bari Aldo Moro) ; Berard, L. (Winnipeg Regional Health Authority) ; Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ; Harris, S.B. (Western University) ; Universitat Autònoma de Barcelona
Achieving target glycaemic control is essential in people with diabetes to minimize the risk of long-term complications, and many people with type 2 diabetes will ultimately require basal insulin (BI) therapy to achieve their individualized glycaemic targets. [...]
2020 - 10.1111/dom.13946
Diabetes, Obesity and Metabolism, Vol. 22 Núm. 5 (january 2020) , p. 722-733  
3.
10 p, 1.7 MB Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes : Barriers and solutions for improving uptake in routine clinical practice / Khunti, Kamlesh (NIHR Applied Research Collaboration - East Midlands) ; Jabbour, Serge (Thomas Jefferson University) ; Cos Claramunt, Francesc Xavier (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ; Mudaliar, Sunder (Veterans Affairs Medical Center) ; Mende, Christian (University of California San Diego) ; Bonaca, Marc (University of Colorado School of Medicine) ; Fioretto, Paola (University of Padua) ; Universitat Autònoma de Barcelona
Recent advances in type 2 diabetes (T2D) research have highlighted the benefits of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, including cardiovascular and renal protection. However, uptake rates of these drugs remain low in patients with T2D, particularly in subpopulations most likely to benefit from them. [...]
2022 - 10.1111/dom.14684
Diabetes, Obesity and Metabolism, Vol. 24 (march 2022) , p. 1187-1196  
4.
6 p, 716.7 KB How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting? / Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ; Westerbacka, J. (Sanofi) ; Nicholls, C. (Sanofi) ; Wu, Jasmanda (Sanofi) ; Gupta, R. (Accenture) ; Eliasson, B. (Department of Medicine. University of Gothenburg. Sahlgrenska University Hospital)
Randomized controlled trial (RCT) populations often do not reflect those typically seen in clinical practice. This retrospective, observational cohort study analysed the real-world data of people with type 2 diabetes (T2DM) prescribed basal insulin analogues from electronic medical records (EMRs) in the Explorys database, which includes data from 39 integrated healthcare systems in the United States, to determine how representative selected RCTs investigating insulin glargine 300 U/mL (Gla-300) are of T2DM populations in a real-world setting. [...]
2021 - 10.1111/dom.14264
Diabetes, Obesity and Metabolism, Vol. 23 Núm. 3 (march 2021) , p. 838-843  
5.
8 p, 1.1 MB Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial / Wysham, Carol (Rockwood Clinic (Spokane, Washington)) ; Bonadonna, Riccardo C (University of Parma) ; Aroda, Vanita R. (Medstar Health Research Institute (Hyattsville, Maryland)) ; Puig Domingo, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Kapitza, Christoph (Profil Institute (Neuss, Alemanya)) ; Stager, William (Sanofi) ; Yu, Christine (Sanofi) ; Niemoeller, Elisabeth (Sanofi) ; Souhami, Elisabeth (Sanofi) ; Bergenstal, Richard M. (International Diabetes Center (Minneapolis, Estats Units)) ; Universitat Autònoma de Barcelona
Aims: To assess the impact of baseline characteristics on clinical outcomes in the LixiLan-L trial, a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks in a population of patients with type 2 diabetes mellitus (T2DM) inadequately controlled on a previous regimen of basal insulin alone or in combination with 1 or 2 oral glucose-lowering drugs. [...]
2017 - 10.1111/dom.12961
Diabetes, Obesity and Metabolism, Vol. 19 (2017) , p. 1408-1415  
6.
10 p, 889.7 KB Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA / Mauricio Puente, Dídac (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Meneghini, Luigi (University of Texas Southwertern Medical Center) ; Seufert, Jochen (Freiburg Universität) ; Liao, Laura (Sanofi, Bridgewater, New Jersey) ; Wang, Hongwei (Sanofi, Bridgewater, New Jersey) ; Tong, Liyue (Sanofi, Bridgewater, New Jersey) ; Cali, Anna M.G (Sanofi, Paris) ; Stella, Peter (Sanofi, Paris) ; Carita, Paulo (Sanofi, Paris) ; Khunti, Kamlesh (University of Leicester. Diabetes Research Centre) ; Universitat Autònoma de Barcelona
Aims: To evaluate short- and long-term glycaemic control and hypoglycaemia incidence in insulin-naïve patients ≥30 years of age with type 2 diabetes (T2DM) initiating basal insulin (BI) with or without oral anti-hyperglycaemic drugs (OADs). [...]
2017 - 10.1111/dom.12927
Diabetes, Obesity and Metabolism, Núm. 19 (2017) , p. 1155-1164  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.